Foghorn Therapeutics entered into a strategic collaboration with Merck to leverage Foghorn’s Gene Traffic Control platform for cancer therapies.
Sanofi Genzyme Executive VP Bill Sibold spoke to BioSpace about the company’s core pipeline focus, programs aimed at COVID-19, and what the future of the industry and patient care could look like in a post-COVID-19 world.
CSL Behring bolstered the company’s growing gene therapy portfolio with the acquisition of global rights to uniQure’s gene therapy program for hemophilia B that has a price tag of up to $2 billion.
San Diego-based Engrail Therapeutics launched with $32 million in a Series A financing round that was solely funded by Nan Fung Life Sciences (NFLS).
Lundbeck is making changes to the global pharma company’s R&D initiative, which could lead to a reduction of up to 160 positions.
Britain’s AstraZeneca clinched expanded regulatory backing for two medications, including one for the blockbuster cancer treatment Lynparza, in a development pipeline that now includes a possible coronavirus vaccine.
After four years as head of Sanofi’s vaccines division, David Loew is departing the pharma giant to take on a new role as chief executive officer of Paris-based Ipsen, effective July 1.
Gilead Sciences and Arcus Biosciences signed a 10-year partnership deal to co-develop and co-commercialize a number of Arcus’ pipeline products.
Diabetes and obesity remain a problem, even during a pandemic. Eli Lilly is developing 13 diabetes drugs in Phase I through Phase III trials, with data from various trials planned for release throughout 2020.
Prellis Biologics Inc. generated 300 human IgG antibodies that bind to either the S1 or S2 spike protein of the SARS-CoV2-Wuhan strain of the novel coronavirus.